Novo Nordisk Expands Obesity Portfolio with Oral Drug Trial
Published on 03/25/2026 at 03:57 | Redaktion boerse-global.de
The Danish pharmaceutical giant is broadening its strategy in the lucrative weight-loss market beyond its established injectable treatments. A new Phase 1 clinical study for an oral medication candidate has commenced, marking a significant strategic shift and triggering an initial payment to a key partner.
Strategic Diversification Amid Market Pressure
Facing intensifying competition in the anti-obesity sector, Novo Nordisk is actively diversifying its development pipeline. The company's reliance on blockbuster drugs like Wegovy is being supplemented by new approaches. The recent initiation of a Phase 1 trial for an oral, non-incretin-based therapy represents a calculated move to secure long-term market share. The first conclusive data from this early-stage study is not expected before early 2027.
The candidate at the center of this development is LX9851, a pill designed to treat obesity and related metabolic conditions. The weekend-launched trial will initially assess safety and dosage in 96 overweight participants. For Lexicon Pharmaceuticals, the licensing partner, the study's start activated an immediate $10 million milestone payment. Should the drug successfully navigate all future clinical and regulatory phases, Lexicon stands to receive up to $1 billion in additional milestone payments, plus future royalties on sales.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Share Buybacks Provide Structural Support
Alongside its research initiatives, Novo Nordisk's management continues to execute its capital return program. As part of this ongoing effort, the company repurchased approximately 7.85 million B-shares for nearly DKK 2.1 billion by March 20, 2026. The broader buyback program, launched in February, is authorized to allocate up to DKK 15 billion over a twelve-month period. These transactions have resulted in the company holding 0.6% of its share capital as treasury stock.
This aggressive repurchase activity serves as a key mechanism to support the firm's capital structure, especially during a period of notable stock price weakness. The equity has recently traded just above its 52-week low, closing at €31.95 in the latest session. Since the start of the year, the share price has declined by 28.50%.
Ad
Novo Nordisk Stock: New Analysis - 25 March
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
